MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis.

FREMONT, Calif., June 16 /PRNewswire/ -- Microfluidic Systems, a privately-held company, announced today that they received patent number 7,541,166, entitled "Sonication to Selectively Lyse Different Cell Types". This method, originally applied to the process of differential extraction of male/fem...

BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus?

LUDWIGSHAFEN, Germany, June 10 /PRNewswire/ -- It doesn't take long after you've polished off a plateful of the delicious vegetable before you are forcefully reminded of it in the restroom. Some people are surprised by the strange odor rising from the bowl after urinating. The unmistakable olf...

Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents

PROENCY will provide real-world clinical data on the PROMUS(TM) Stent NATICK, Mass., Feb. 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that the first patient has been enrolled in its PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European registry....

WiscNet members choose anti-spam products for different needs

Members of WiscNet , a non-profit cooperative that networks Wisconsin institutions, took different directions in choosing anti-spam software after a test conducted with eWeek last September, the magazine has reported. After months of seeking out anti-spam systems, examining more than 30 respo...

Benchmark Plus Microplate Reader: Quantitation of Protein Concentration Using Two Different Colorimetric Assay Kits, Rev A

Theresa Redila-Flores, Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules, CA 94547 USA The Bradford and Lowry assays are 2 colorimetric assays that are commonly used to quantitate protein concentration. Bio-Rads protein assay (catalog ...

Comparison of Performance Characteristics of Different Biolistic Devices

back to top ...

Commercial Plasmid Preparation Methods Yield DNA With Different Transfection Capabilities

Kathleen A. Maguire-Zeiss, Brandon K. Harv e y, Rita E. Giuliano and H o w a rd J. Federo ff, University of Rochester, Rochester, NY, USA Introduction Transfection efficiency is dependent upon a number of factors, including method of transfection...

Comparison of Different Methods of mRNA Quantitation

Feature Nuclease Protection Assays Northern Blotting RT-PCR ...

Comparison of different protein quantitation methods

This application note compares the accuracy and reproducibility of absolute protein quantitation of the Agilent 2100 bioanalyzer in combination with the Protein 200 Plus assay to the batch-based methods Lowry and Bradford...

The TripleMaster PCR System for three different amplifications

Christian Rohrer, Eppendorf AG Introduction Standard PCR components (Taq polymerase and reaction buffers) are used for the general amplification of relatively short DNA fragments ...

Growth spurts

... and spurts, driven by "coalescence events," in which small crystals randomly collide and fuse together into larger crystals. Despite their distinctly different growth trajectories, these two processes ultimately yield a nearly monodisperse distribution of nanocrystals, meaning the crystals are all approximate...

Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading

...ists. "The studies did not use a true control group condition, where patients would receive no treatment. The 'control' patients actually received a different effective treatment and both groups demonstrated highly clinically significant reductions in pain. This demonstrates that vertebroplasty is an effect...

ThermoGenesis Announces Expanded Collaboration With Celling Technologies

... scheduled for fiscal years 2009 and 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. A more complete description of these and othe...

ThermoGenesis Provides Update on Fiscal 2009 Results

... scheduled for fiscal years 2009 and 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. Revenue and loss are unaudited estimates, and ...

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

...erapy. "This research represents an entirely new way of looking at the treatment of solid tumor cancers, recognizing that tumors are made up of different types of cells and targeting cancer stem cells has a profound effect on tumor growth and recurrence," said Paul Hastings, President and Chief Executiv...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and othe...

PDI Reports 2009 Second Quarter Financial Results

... control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, a...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...5 million as compared to $7.4 million in the same period in 2008. Amicus recorded revenue during the second quarter of 2009 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as re...

CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform

...nalysis," noted Dr. Jing Cheng, CEO and Founder of CapitalBio. "The LuxScan scanners have a wide depth of field which can capture accurate images from different types of microarrays and from tissue arrays. The combination of these scanning advantages with MicroVigene software provides enhanced analysis possibi...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...., the ends of the degenerating neurons), located in an area of the brain called the putamen. The cell bodies for these same neurons are located in a different area of the brain, called the substantia nigra. Once CERE-120 is delivered to the brain, it provides stable, long-lasting expression of neurturin in ...

NxStage Reports Second Quarter 2009 Financial Results

...asis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considere...

Next Safety Releases Advanced Respirator for Infectious Diseases

... Next Safety is a leader in the development of pulmonary health products. It has a product line of advanced respirators that were developed for many different applications. The company also develops pulmonary drug delivery products. It is a leader in the development of nicotine delivery devices for ...

Saint-Gobain Introduces Next Generation Silicone Tubing

...temperatures -- -80 degrees F to 500 degrees F (-62 degrees C to 260 degrees C). Sani-Tech(R) Ultra is available in 50 and 65 durometers and 91 different ID/OD combinations. Available options include bulk spool packaging and pre-delivery gamma irradiation. Custom sizes, lengths, durometers and laylines ...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

...ial of radezolid in the treatment of community-acquired pneumonia (CAP). In the double-blind study, radezolid was administered orally at three different doses: 300 mg once daily (QD), 450 mg QD and 450 mg twice daily (BID). This novel oxazolidinone showed comparable efficacy across all three doses, wit...

Plastics that convert light to electricity could have a big impact

...adily extrapolated to other materials. The materials were baked together at different temperatures and for different lengths of time. Ginger is the lead author of a paper documenting the w...

Micromet Closes $80.5 Million Public Offering of Common Stock

... This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include s...

Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist

... uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties re...

VIASPACE Pursuing Renewable Energy Business in Asia

... from growing cotton - are seasonal, since harvests of those crops occur at different times, and the fuel quality of the waste varies with each crop. To reduce t...l results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Such f...

Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures

...statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other fact...

ETC Biomedical Announces Chamber Sale in India

...ainties and assumptions about ETC and its subsidiaries that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These forw...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include s...

Jatropha Couple Oil Crop Cultivation Technology Commercially Released

...that, "Jatropha plantation occupy about 50% of the planted land and to utilized the rest of land in sustainable manner we have been experimenting different intercropping options, patterns and agro- technologies. We have been in search of such an inter-crop for Jatropha which should be oil bearing like Jat...

Bacteria pack their own demise

...oli bacteria, more commonly known as E.coli, have such a T-A system in five different locations in their DNA, while Mycobacterium tuberculosis bacteria even have...ficult feat to pull off, requiring the simultaneous use of a whole range of different technologies. One of the difficulties for instance lay in the fact that par...

R-Tech Ueno Notifies R&D Items

...lammation while the latter detoxifies amine in the living body by its amine oxidase activity. In other words, VAP-1 is a protein that demonstrates two different functions. The increase in VAP-1/SSAO activity is observed in the serum and various tissues of patients with diabetes mellitus, atopic dermatitis, obe...

TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction

...tements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to ...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

...h forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and earl...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...h forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and earl...

Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose

... data expand upon the results we announced in June and support our belief that our influenza vaccines are also capable of providing protection against different circulating viral strains," said Andy Sheldon, President and CEO of Medicago. "Unlike current vaccine manufacturers that have experienced difficulties...

Micromet Announces Pricing of Public Offering of Common Stock

... This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include s...

SyntheMed Receives US Patent on Novel Polymer Technology

...ertainties and other factors which may cause the actual results, performance or achievements of the c om pany, or industry results, to be materially different fr om any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties inclu...

Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS